Breaking
Friday, June 19, 2026
Whitepaper EU Score 85/100

The 2024 EU GMP Annex 1 Revision: A Technical Roadmap for Holistic Contamination Control and Quality Risk Management in Sterile Manufacturing

This review discusses the 2024 revision of EU GMP Annex 1, focusing on contamination control and quality risk management in sterile manufacturing.

Publisher
International Journal of Pharmaceutical Sciences
Published
Length
15 pages
File
4.2 MB PDF
The 2024 EU GMP Annex 1 Revision: A Technical Roadmap for Holistic Contamination Control and Quality Risk Management in Sterile Manufacturing — cover

Quick answer

The 2024 EU GMP Annex 1 Revision: A Technical Roadmap for Holistic Contamination Control and Quality Risk Management in Sterile Manufacturing is a 15-page whitepaper from International Journal of Pharmaceutical Sciences covering EU pharma intelligence. This review discusses the 2024 revision of EU GMP Annex 1, focusing on contamination control and quality risk management in sterile manufacturing.

Research library Data sources More from International Journal of Pharmaceutical Sciences

High impact International Journal of Pharmaceutical Sciences 7 min read

Why this matters

This review discusses the 2024 revision of EU GMP Annex 1, focusing on contamination control and quality risk management in sterile manufacturing.

Executive summary

  • This review discusses the 2024 revision of EU GMP Annex 1, focusing on contamination control and quality risk management in sterile manufacturing.

Market Impact

Regulatory high
Commercial high
Competitive medium
Investment high

Who should read this

  • EU market access specialists

Ask about this report

AI-assisted answers grounded in NovaPharmaNews intelligence

Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.

Download the full 15-page PDF

Free · 4.2 MB · Instant access after email

🔒 We never share your email. Single-click download.
# Executive Summary This whitepaper reviews the 2024 revision of EU GMP Annex 1, emphasizing a holistic approach to contamination control in sterile manufacturing. Key findings include: - Transition from prescriptive compliance to a risk-based framework centered on Quality Risk Management (QRM). - Mandatory implementation of a site-wide Contamination Control Strategy (CCS) to ensure sterility assurance. - Adoption of advanced barrier technologies and absolute zero-CFU expectations in Grade A zones. - Identification of significant operational and economic challenges for legacy facilities and small-to-medium manufacturers. - Insights for regulators and quality professionals navigating compliance with the revised standards.

Frequently asked questions

What whitepapers does NovaPharmaNews publish?

Our research library curates FDA, EMA, and industry publisher PDFs — regulatory guidance, clinical analyses, manufacturing reports, and market intelligence. Each report includes an AI-summarized landing page with key takeaways and a gated PDF download.

How do I download a whitepaper?

Open any report page, scroll to the download form, and enter your work email. You receive instant PDF access and can opt in to weekly pharma intelligence updates. Downloads are free for healthcare professionals.

How do whitepapers connect to news and pipeline data?

Report pages link to related intelligence — company profiles, drug INN pages, clinical trials, pipeline programs, and topic hubs. Use the intelligence spokes on each page to explore the entity graph behind the research.

Ready to read the full report?

Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.

Download PDF

Related topic hubs

Editorial coverage and intelligence directories for this report's beat.

Explore the intelligence platform